The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting

Huang,Jian; Wang,Xiao-Jia; Yu,Ding; Jin,Ye-Ning; Zhen,Lei-Zhen; Xu,Nong; Liu,Wei; Deng,Yong-Chuan; Wu,Shi-Xiu; He,Jia

doi:10.3892/etm.2013.996

The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting

Authors:
- Jian Huang
- Xiao-Jia Wang
- Ding Yu
- Ye-Ning Jin
- Lei-Zhen Zhen
- Nong Xu
- Wei Liu
- Yong-Chuan Deng
- Shi-Xiu Wu
- Jia He
View Affiliations

Affiliations: Zhejiang Cancer Hospital, Hangzhou 310022, P.R. China, Hubei Cancer Hospital, Wuhan 430079, P.R. China, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou 310009, P.R. China, Hebei Cancer Hospital, Shijiazhuang 050011, P.R. China, The Second Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou 310008, P.R. China, The First Affiliated Hospital of Wenzhou Medical College, Hangzhou 325000, P.R. China, Health Statistics Teaching and Research Section, The Second Army Medical University, Shanghai 200433, P.R. China
Published online on: March 8, 2013 https://doi.org/10.3892/etm.2013.996
Pages: 1418-1426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to evaluate the efficacy and safety of palonosetron hydrochloride injection for preventing chemotherapy-induced moderate and severe nausea and vomiting. A multi-centered, randomly stratified, double-blind, double-dummy, parallel-group and positive-controlled trial was performed. A total of 240 patients who underwent chemotherapy treatment which induced moderate or severe vomiting were divided into the experimental and control groups. Half an hour before chemotherapy, the experimental group received a 0.25-mg palonosetron hydrochloride injection, whereas the control group received a 3-mg granisetron injection. The acute vomiting complete remission rate (CRR) of the experimental group was not significantly different compared with that of the control group (P=0.35). The delayed vomiting CRR of the experimental group was significantly higher compared with that of the control group (P=0.002). No difference in full course vomiting CRR, vomiting control time, treatment failure time or acute nausea CRR was identified between the two groups. No significant differences in adverse events were observed between the experimental group and the control group. No significant differences in adverse reactions occurred between the experimental group and the control group (12.50%). Palonosetron hydrochloride injection had a better effect on delayed vomiting CRR than granisetron hydrochloride injection. The two injections exhibited similar effects on acute vomiting CRR, full course vomiting CRR, vomiting control time, treatment failure time (days), acute nausea CRR and adverse events.

View Figures

View References

1.	Dempsey CL, Coop AJ, Shillington A, Farley PA, Eberhardt DR and O’Briant S: Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. Am J Health Syst Pharm. 61:781–786. 2004.PubMed/NCBI
2.	Geling O and Eichler HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications J Clin Oncol. 23:1289–1294. 2005.PubMed/NCBI
3.	Hesketh PJ: Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 18:163–173. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Jordan K, Hinke A, Grothey A, et al: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 15:1023–1033. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Yonemura M, Katsumata N, Hashimoto H, et al: Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol. 39:443–448. 2009. View Article : Google Scholar
6.	Rubenstein EB: Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2:284–289. 2004.PubMed/NCBI
7.	Kris MG, Gralla RJ, Clark RA, et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 3:1379–1384. 1985.PubMed/NCBI
8.	National Comprehensive Cancer Network: Antiemesis; V.2. 2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdfuri. Accessed April 1, 2009.
9.	National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfuri. Accessed August 9, 2006.
10.	Roila F, Boschetti E, Tonato M, et al: Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 14:238–242. 1991. View Article : Google Scholar : PubMed/NCBI
11.	Balu S, Buchner D, Craver C and Gayle J: Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting. Clin Ther. 33:443–455. 2011. View Article : Google Scholar
12.	Ito H, Akuzawa S, Tsutsumi R, et al: Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex. Neuropharmacology. 34:631–637. 1995. View Article : Google Scholar : PubMed/NCBI
13.	Eglen RM, Lee CH, Smith WL, et al: Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol. 114:860–866. 1995. View Article : Google Scholar : PubMed/NCBI
14.	Piraccini G, Stolz R, Tei M, et al: Pharmacokinetic Features of a Novel 5-HT3-Receptor Antagonist: Palonosetron (RS-25259-197). Proc Am Soc Clin Oncol. 20:4002001.
15.	Wong EH, Clark R, Leung E, et al: The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 114:851–859. 1995. View Article : Google Scholar : PubMed/NCBI
16.	Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E and Pegoretti B: Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemo-therapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 19:823–832. 2011. View Article : Google Scholar
17.	Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 19:1759–1767. 2001.PubMed/NCBI
18.	de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A and Verweij J: Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 85:1099–1101. 2001.
19.	Gralla RJ, de Wit R, Herrstedt J, et al: Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 104:864–868. 2005.
20.	de Wit R, Herrstedt J, Rapoport B, et al: The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 40:403–410. 2004.